blinatumomab
Sign in to saveBlinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used for the treatment of Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that specifically targets the CD19 antigen present on B cells. Blinatumomab is given via intravenous infusion.
In the Vinony graph
Within Vinony's link graph, blinatumomab is referenced by 356 other articles, and connects out to T-lymphocytes, monoclonal antibody and Philadelphia chromosome.
It sits within the topics Chemicals that do not have a ChemSpider ID assigned, Drugboxes which contain changes to verified fields and Drugboxes which contain changes to watched fields.
Its subject is documented across 14 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 459980828
- Drug.type
- mab
- Drug.mab_type
- BiTE
- Drug.source
- o
- Drug.target
- CD19, CD3
- Drug.tradename
- Blincyto
- Drug.MedlinePlus
- a614061
- Drug.DailyMedID
- Blinatumomab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FX07
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
via Wikipedia infobox
Wikidata facts
- Official website
- www.blincyto.com
- Has use
- medication
Show 3 more facts
- subject has role
- monoclonal antibody
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~5 min read
Encyclopedic overview
6 sectionsContents
- Medical use
- Mechanism of action
- History
- Society and culture
- Economics
- References
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used for the treatment of Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that specifically targets the CD19 antigen present on B cells. Blinatumomab is given via intravenous infusion.
Blinatumomab was approved for medical use in the United States in December 2014, in Australia in November 2015, in Canada in March 2016, and in the European Union in November 2023. It is on the World Health Organization's List of Essential Medicines.
Excerpted from Wikipedia’s “blinatumomab” article, available under the CC BY-SA 4.0 licence.